Literature DB >> 8825086

Cloning and characterization of the genes encoding the hemolysin of Haemophilus ducreyi.

K L Palmer1, R S Munson.   

Abstract

We previously identified a heat- and protease-labile haemolytic activity expressed by Haemophilus ducreyi. In order to characterize the haemolysin at the molecular level, genomic DNA from H. ducreyi was probed with haemolysin genes from other Gram-negative organisms. The haemolysin genes of Proteus mirabilis hybridized to H. ducreyi DNA suggesting that the haemolysin of H. ducreyi is related to the Proteus/Serratia pore-forming family of haemolysins. Tn916 mutagenesis was employed to isolate haemolysin-deficient mutants. Approximately 5000 Tn916 transposon mutants were screened for the loss of haemolytic activity and two mutants were identified. One mutant, designated 35,000-1, was further characterized. Sequences flanking the Tn916 element in strain 35,000-1 were employed to identify clones from a lambda DASHII library of H. ducreyi strain 35,000 DNA. A 13 kb insert from one lambda clone was selected for further study. This 13 kb fragment was able to both confer haemolytic activity to Escherichia coli and complement the haemolysin deficiency in strain 35,000-1. The haemolysin gene cluster was cloned from this 13 kb insert and two genes, designated hhdA and hhdB, were identified. The derived amino acid sequence of these genes demonstrated homology to the haemolysin and activation/secretion proteins of P. mirabilis and Serratia marcescens.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8825086     DOI: 10.1111/j.1365-2958.1995.18050821.x

Source DB:  PubMed          Journal:  Mol Microbiol        ISSN: 0950-382X            Impact factor:   3.501


  42 in total

1.  Transcription of candidate virulence genes of Haemophilus ducreyi during infection of human volunteers.

Authors:  R E Throm; S M Spinola
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

2.  Identification of a locus involved in systemic dissemination of Yersinia enterocolitica.

Authors:  K M Nelson; G M Young; V L Miller
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

Review 3.  Immunopathogenesis of Haemophilus ducreyi infection (chancroid).

Authors:  Stanley M Spinola; Margaret E Bauer; Robert S Munson
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

4.  Activation of Serratia marcescens hemolysin through a conformational change.

Authors:  Georg Walker; Ralf Hertle; Volkmar Braun
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

5.  Expression of the cytolethal distending toxin in a geographically diverse collection of Haemophilus ducreyi clinical isolates.

Authors:  K Kulkarni; D A Lewis; C A Ison
Journal:  Sex Transm Infect       Date:  2003-08       Impact factor: 3.519

6.  The LspB protein is involved in the secretion of the LspA1 and LspA2 proteins by Haemophilus ducreyi.

Authors:  Christine K Ward; Jason R Mock; Eric J Hansen
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

7.  The cytolethal distending toxin from the chancroid bacterium Haemophilus ducreyi induces cell-cycle arrest in the G2 phase.

Authors:  X Cortes-Bratti; E Chaves-Olarte; T Lagergård; M Thelestam
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

8.  Haemophilus ducreyi hemolysin acts as a contact cytotoxin and damages human foreskin fibroblasts in cell culture.

Authors:  M J Alfa; P DeGagne; P A Totten
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

9.  Identification of tandem genes involved in lipooligosaccharide expression by Haemophilus ducreyi.

Authors:  M K Stevens; J Klesney-Tait; S Lumbley; K A Walters; A M Joffe; J D Radolf; E J Hansen
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

10.  Cloning and characterization of tdhA, a locus encoding a TonB-dependent heme receptor from Haemophilus ducreyi.

Authors:  C E Thomas; B Olsen; C Elkins
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.